Less Ads, More Data, More Tools Register for FREE

Pin to quick picksIQ-AI Regulatory News (IQAI)

  • There is currently no data for IQAI

EPT Disclosure

12 Sep 2008 08:53

RNS Number : 3067D
Liberum Capital Limited
12 September 2008
 

 

DEALINGS BY CONNECTED EXEMPT PRINCIPAL TRADERS 

WITHOUT RECOGNISED INTERMEDIARY STATUS, OR WITH RI STATUS

BUT NOT DEALING IN A CLIENT-SERVING CAPACITY

(Rule 38.5(b) of the Takeover Code)

1. KEY INFORMATION

Name of exempt principal trader

Liberum Capital Limited

Company dealt in

Flying Brands

Class of relevant security to which the dealings being disclosed relate (Note 1)

Units comprising 1 ordinary 1p share and 1 A ordinary of 0.005p share

Date of dealing

11/09/08

2. INTERESTS, SHORT POSITIONS AND RIGHTS TO SUBSCRIBE

(a) Interests and short positions (following dealing) in the class of relevant security dealt in (Note 2)

Long

Short

Number (%)

Number (%)

(1) Relevant securities 

8,964 0.04%

0 0%

(2) Derivatives (other than options)

(3) Options and agreements to purchase/sell

Total

8,964 0.04%

0 0%

(b) Interests and short positions in relevant securities of the company, other than the class dealt in (Note 2)

Class of relevant security:

Long

Short

Number (%)

Number (%)

(1) Relevant securities 

(2) Derivatives (other than options)

(3) Options and agreements to purchase/sell

Total

Rights to subscribe (Note 2)

Class of relevant security:

Details

3. DEALINGS (Note 3)

(a) Purchases and sales

Purchase/sale

Number of securities

Price per unit (Note 4)

Purchase 

2,000

0.675p

Sale

54,345

0.67p

(b) Derivatives transactions (other than options)

Product name, 

e.g. CFD

Long/short (Note 5)

Number of securities (Note 6)

Price per unit (Note 4)

(c) Options transactions in respect of existing securities

(i) Writing, selling, purchasing or varying

Product name,

e.g. call option

Writing, selling, purchasing, varying etc.

Number of securities to which the option relates (Note 6)

Exercise

price 

Type, e.g. American, European etc.

Expiry 

date

Option money

paid/received per unit (Note 4) 

(ii) Exercising

Product name, e.g. call option

Number of securities 

Exercise price per unit (Note 4)

(d) Other dealings (including new securities) (Note 3)

Nature of transaction (Note 7)

Details

Price per unit (if applicable) (Note 4)

4. OTHER INFORMATION

Agreements, arrangements or understandings relating to options or derivatives

Full details of any agreement, arrangement or understanding between the person disclosing and any other person relating to the voting rights of any relevant securities under any option referred to on this form or relating to the voting rights or future acquisition or disposal of any relevant securities to which any derivative referred to on this form is referenced. If none, this should be stated.

None

Is a Supplemental Form 38.5(b) attached? (Note 8) NO

Date of disclosure

12/09/08

Contact name

Carl Chambers 

Telephone number

020 3100 2000

Name of offeree/offeror with which connected

West Coast Capital

Nature of connection (Note 9)

Adviser

Notes

The Notes on Form 38.5(b) can be viewed on the Takeover Panel's website at www.thetakeoverpanel.org.uk

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
EMMSFESWESASEIU
Date   Source Headline
18th Aug 202311:20 amRNSIB & GE HealthCare Enter into Commercial Agreement
17th Aug 20237:00 amRNSHalf-year Report
19th Jul 20237:00 amRNSImaging Biometrics Installs IB Nimble™ For MCW
13th Jul 20237:00 amRNSOrphan Drug Designation for GaM in Pediatric GBM
27th Jun 20237:00 amRNSStudies Show GaM Inhibits Pediatric Tumor Growth
23rd May 202311:02 amRNSResult of AGM
23rd May 20237:00 amRNSAGM Statement
3rd May 20234:14 pmRNSNotice of AGM
26th Apr 20237:00 amRNSFinal Results
28th Feb 20233:52 pmRNSOrphan Drug Designation Status
13th Jan 20232:05 pmRNSSecond Price Monitoring Extn
13th Jan 20232:00 pmRNSPrice Monitoring Extension
13th Jan 202311:05 amRNSSecond Price Monitoring Extn
13th Jan 202311:00 amRNSPrice Monitoring Extension
10th Jan 20237:00 amRNSLetter to Shareholders
2nd Dec 202211:11 amRNSHolding in Company
25th Oct 202211:00 amRNSPrice Monitoring Extension
30th Sep 20227:00 amRNSLetter to Shareholders
26th Sep 20227:00 amRNSIssue of Warrants to Employees
16th Aug 20224:40 pmRNSSecond Price Monitoring Extn
16th Aug 20224:35 pmRNSPrice Monitoring Extension
16th Aug 20229:28 amRNSHalf-year Report
3rd Aug 20221:01 pmRNSTR1 - Notification of Major Holdings
11th Jul 20227:00 amRNSImaging Biometrics Announces Channel Partnership
31st May 202211:05 amRNSSecond Price Monitoring Extn
31st May 202211:00 amRNSPrice Monitoring Extension
31st May 20228:00 amRNSSubmission of FDA 510(k) Application for IB Zero G
30th May 202210:47 amRNSResult of AGM
5th May 20223:00 pmRNSNotice of AGM
3rd May 20222:21 pmRNSIB Broadens Quantitative Mapping
28th Apr 20225:52 pmRNSFinal Results
9th Mar 20223:08 pmRNSIQAI’s Sponsored Phase I Clinical Trial is Open
28th Feb 202211:12 amRNSTotal Voting Rights
8th Feb 20227:00 amRNSIssue of shares to Mayo Clinic
27th Jan 20227:00 amRNSImaging Biometrics LLC - Letter to Shareholders
4th Jan 20229:27 amRNSDirector/PDMR Shareholding
17th Dec 20217:37 amRNSIQ-AI Prepares for Phase I Clinical Trial Launch
13th Dec 202110:32 amRNSDirector's Interest
11th Nov 20218:52 amRNSAgreement with St. Jude Children’s Hospital
2nd Nov 20218:19 amRNSMD ANDERSON ADOPTS IB CLINIC
28th Oct 20214:00 pmRNSLetter to Shareholders
7th Oct 20214:41 pmRNSSecond Price Monitoring Extn
7th Oct 20214:36 pmRNSPrice Monitoring Extension
7th Oct 20212:05 pmRNSSecond Price Monitoring Extn
7th Oct 20212:00 pmRNSPrice Monitoring Extension
7th Oct 202112:00 pmRNSPlacing
1st Oct 20218:17 amRNSCase Report on Clinical Value of IB Software
22nd Sep 20217:00 amRNSEU PATENT FOR DUAL-ECHO MR PERFUSION PROCESSSING
17th Sep 20217:00 amRNSIB Software Chosen for Accuracy and Automation
10th Sep 20217:00 amRNSUpdate on Phase I Clinical Trial

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.